Table 3.
Number of patients (%) | ||
---|---|---|
Low risk | 21 (53.8%) | |
Intermediate risk | 5 (12.8%) | |
ESGO Clinical Risk Group | High-intermediate risk | 2 (5.1%) |
High risk | 10 (25.6%) | |
Advanced metastatic | 1 (2.6%) | |
Low risk | 22 (56.4%) | |
Intermediate risk | 4 (10.3%) | |
Integrated molecular risk | High-intermediate risk | 3 (7.7%) |
High risk | 9 (23.1%) | |
Advanced metastatic | 1 (2.6%) |
ESGO = European Society of Gynaecological Oncology